Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics

Investing in cutting-edge companies is a bit riskier than investing in tried-and-tested players, but breaking new ground can sometimes offer outsized rewards. On that note, Editas Medicine (EDIT -4.72%) and Intellia Therapeutics (NTLA -3.02%) are both exciting gene-editing businesses that aspire to treat or cure human illnesses using some of the most advanced biotechnologies that exist at the moment.But there's a clear winner of this matchup when it comes to which is the more attractive opportunity to inves ...